Avadel pharmaceuticals reiterates 2025 guidance as it reports fourth quarter and full year 2024 financial results

-- lumryz™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published january 8 -- reiterates 2025 guidance, with the number of patients on lumryz expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million -- executing multiple initiatives to accelerate patient demand for lumryz -- patient enrollment is on track in the phase 3 revitalyz™ study to evaluate efficacy and safety of lumryz in idiopathic hypersomnia (ih) -- avadel management to host a conference call today at 8:30 a.m. et dublin, march 03, 2025 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial results for the fourth quarter and full year ended december 31, 2024.
AVDL Ratings Summary
AVDL Quant Ranking